| Literature DB >> 17938741 |
Jonathan Chevrier1, Brenda Eskenazi, Asa Bradman, Laura Fenster, Dana B Barr.
Abstract
BACKGROUND: Studies have reported that prenatal exposure to polychlorinated biphenyls (PCBs) may alter neurodevelopment in both humans and animals. Furthermore, prenatal exposure to some PCB congeners and commercial mixtures has been shown to decrease free and total thyroxine (T(4)) blood levels in animals. Because thyroid hormones (TH) are essential for normal neurologic development, it has been suggested that the deleterious neurodevelopmental effect of PCBs may occur through TH disruption. PCBs may in turn affect TH levels by inducing the microsomal enzyme uridinediphosphate glucuronosyltransferase (UDP-GT), which is involved in TH elimination.Entities:
Keywords: TSH; UDP-glucuronosyltransferase; cytochrome P450; enzyme inducers; in utero; microsomal enzymes; neonatal; polychlorinated biphenyls; prenatal; thyroid hormone
Mesh:
Substances:
Year: 2007 PMID: 17938741 PMCID: PMC2022659 DOI: 10.1289/ehp.9843
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
References supporting microsomal enzyme induction by individual PCB congeners in animals.
| Microsomal enzymes
| |||
|---|---|---|---|
| PCB congener | UDP-GT | CYP1A/EROD | CYP2B/PROD |
| 42 | |||
| 47 | |||
| 52 | |||
| 77 | |||
| 99 | |||
| 101 | |||
| 105 | |||
| 118 | |||
| 126 | |||
| 128 | |||
| 149 | |||
| 153 | |||
| 154 | |||
| 156 | |||
| 163 | |||
| 169 | |||
| 170 | |||
| 180 | |||
| 183 | |||
| 187 | |||
| 189 | |||
| 194 | |||
| 199 | |||
Demographic characteristics in a population of pregnant women and their children in the Salinas Valley, CA (n = 285).
| Sum PCBs (ng/g lipids) | |||
|---|---|---|---|
| No. (%) | Geometric mean | 95% CI | |
| Maternal | |||
| Age (years) | |||
| 18–24 | 142 (50) | 54.1 | 49.2–59.5 |
| 25–29 | 89 (31) | 59.9 | 53.1–67.5 |
| 30–34 | 35 (12) | 72.9 | 60.2–88.3 |
| 35–45 | 19 (7) | 87.5 | 72.3–105.9 |
| Race | |||
| White | 3 (1) | 38.9 | 9.7–156.3 |
| Latina | 275 (96) | 59.9 | 55.9–64.2 |
| Other | 7 (2) | 67.3 | 50.2–90.3 |
| Education | |||
| ≤6th grade | 118 (41) | 55.7 | 50.1–62.0 |
| 7–12th grade | 100 (35) | 59.4 | 53.0–66.5 |
| ≥High school | 67 (23) | 68.5 | 60.1–78.1 |
| Income (% poverty) | |||
| < 100 | 162 (61) | 59.3 | 54.3–64.7 |
| 100–200 | 96 (36) | 60.5 | 53.7–68.2 |
| > 200 | 9 (3) | 49.1 | 29.9–80.4 |
| Country of birth | |||
| United States | 34 (12) | 61.9 | 50.0–76.5 |
| Mexico | 244 (86) | 59.8 | 55.6–64.3 |
| Other | 7 (3) | 52.0 | 34.5–78.6 |
| Time in the USA (years) | |||
| ≤5 | 156 (55) | 59.0 | 53.7–64.7 |
| 6–10 | 69 (24) | 61.3 | 53.4–70.4 |
| ≥11 | 60 (21) | 60.4 | 52.5–69.5 |
| Parity | |||
| 0 | 103 (36) | 61.6 | 54.8–69.2 |
| ≥1 | 183 (64) | 58.8 | 54.2–63.9 |
| Smoking during pregnancy | |||
| Yes | 12 (4) | 68.7 | 48.5–97.3 |
| No | 274 (96) | 59.5 | 55.5–63.7 |
| Infant | |||
| Sex | |||
| Male | 147 (52) | 58.2 | 52.9–63.9 |
| Female | 138 (48) | 61.6 | 56.0–67.8 |
| Birth weight (g) | |||
| < 2,500 | 9 (3) | 66.8 | 49.9–89.4 |
| 2,500–3,500 | 150 (52) | 58.6 | 53.3–64.4 |
| > 3,500 | 126 (44) | 60.8 | 55.0–67.2 |
| Gestational age at birth (weeks) | |||
| < 37 | 22 (8) | 61.4 | 49.7–75.7 |
| 37–42 | 264 (92) | 59.7 | 55.6–64.1 |
| > 42 | 0 (0) | — | — |
PCBs with a detection frequency ≥75% were summed.
p < 0.05 ANOVA.
p < 0.05 linear trend by Pearson’s correlation.
PCB levels (geometric means), detection frequencies, ranges, and LOD ranges in a population of pregnant women in the Salinas Valley, CA.
| No. | LOD range | Detection frequency (%) | Geometric mean | 95% CI | Range | |
|---|---|---|---|---|---|---|
| ∑PCBs | 285 | 0.02–1.92 | 100 | 59.8 | 56.0–64.0 | 15.3–323.7 |
| TEQ (pg/g) | 285 | 0.004–0.086 | 100 | 0.86 | 0.75–0.97 | < LOD–5.17 |
| Inducers | 285 | 0.03–1.44 | 100 | 38.9 | 36.3–41.6 | 10.0–250.3 |
| Mono- | 285 | 0.03–1.11 | 100 | 29.4 | 27.2–31.7 | 6.4–127.7 |
| Di- | 285 | 0.03–1.44 | 100 | 27.6 | 25.9–29.5 | 7.3–213.1 |
| Wolff method | ||||||
| Group 1 | 285 | 0.03–1.92 | 100 | 8.3 | 7.6–9.1 | 0.4–62.9 |
| Group 2 | 285 | 0.03–1.11 | 100 | 13.2 | 12.3–14.1 | 2.1–69.1 |
| Group 3 | 285 | 0.04–1.09 | 100 | 8.4 | 7.7–9.1 | 0.6–138.0 |
| Individual congeners | ||||||
| PCB-18 (ng/g) | 279 | 0.03–0.88 | 100 | 6.5 | 5.9–7.1 | 0.9–32.1 |
| PCB-28 (ng/g) | 285 | 0.03–0.79 | 100 | 17.4 | 15.8–19.1 | 3.1–91.7 |
| PCB-44 (ng/g) | 238 | 0.06–1.92 | 98.7 | 2.3 | 2.1–2.6 | < LOD–11.4 |
| PCB-49 (ng/g) | 250 | 0.05–1.40 | 99.2 | 1.5 | 1.4–1.7 | < LOD–7.9 |
| PCB-52 (ng/g) | 261 | 0.05–1.89 | 99.2 | 3.0 | 2.7–3.3 | < LOD–12.4 |
| PCB-66 (ng/g) | 276 | 0.39–1.02 | 100 | 2.8 | 2.5–3.0 | 0.4–16.0 |
| PCB-74 (ng/g) | 276 | 0.04–1.11 | 100 | 4.1 | 3.8–4.4 | 0.7–20.8 |
| PCB-99 (ng/g) | 263 | 0.06–1.09 | 100 | 1.8 | 1.7–1.9 | 0.5–11.6 |
| PCB-101 (ng/g) | 241 | 0.06–1.44 | 94.6 | 0.9 | 0.8–1.1 | < LOD–5.8 |
| PCB-118 (ng/g) | 270 | 0.05–0.86 | 99.6 | 3.4 | 3.2–3.7 | < LOD–4.7 |
| PCB-138 (ng/g) | 263 | 0.03–0.65 | 100 | 2.5 | 2.3–2.7 | 0.2–30.9 |
| PCB-146 (ng/g) | 249 | 0.05–0.60 | 87.6 | 0.5 | 0.4–0.5 | < LOD–14.7 |
| PCB-153 (ng/g) | 273 | 0.04–0.70 | 100 | 5.6 | 5.2–6.0 | 0.3–95.6 |
| PCB-156 (ng/g) | 270 | 0.07–0.55 | 85.2 | 0.4 | 0.4–0.5 | < LOD–6.3 |
| PCB-180 (ng/g) | 231 | 0.06–0.96 | 100 | 1.5 | 1.4–1.7 | 0.3–30.0 |
| PCB-183 (ng/g) | 259 | 0.06–0.47 | 78.0 | 0.3 | 0.3–0.4 | < LOD–8.2 |
| PCB-187 (ng/g) | 224 | 0.04–0.71 | 96.9 | 0.9 | 0.8–1.0 | < LOD–38.3 |
| PCB-194 (ng/g) | 263 | 0.03–0.50 | 95.4 | 0.5 | 0.5–0.6 | < LOD–8.6 |
| PCB-199 (ng/g) | 271 | 0.03–0.62 | 85.6 | 0.4 | 0.3–0.4 | < LOD–7.5 |
Sum of all PCBs with a detection frequency ≥ 75% (listed above).
Enzyme inducers include PCBs 52, 99, 101, 118, 153, 156, 180, 183, 187, 194, and 199.
Mono-ortho PCBs include PCBs 28, 66, 74, 118, and 156.
Di-ortho PCBs include PCBs 18, 44, 49, 52, 99, 101, 138, 146, 153, 180, and 194.
Group 1 includes PCBs 44, 49, 52, 101, 187, and 199.
Group 2 includes PCBs 66, 74, 118, 138, and 156.
Group 3 includes PCBs 99, 153, 180, and 183.
Age-adjusted and fully adjusted associations between prenatal exposure to PCBs and neonatal TSH levels.
| Age-adjusted
| Fully adjusted
| |||
|---|---|---|---|---|
| β | 95% CI | β | 95% CI | |
| ∑PCBs | 0.05 | −0.05 to 0.15 | 0.06 | −0.05 to 0.16 |
| TEQ | −0.01 | −0.10 to 0.08 | 0.00 | −0.10 to 0.09 |
| Inducers | 0.09 | −0.01 to 0.19 | 0.11 | 0.01 to 0.21 |
| Mono- | 0.01 | −0.08 to 0.10 | 0.01 | −0.08 to 0.10 |
| Di- | 0.08 | −0.03 to 0.19 | 0.09 | −0.02 to 0.20 |
| Wolff method | ||||
| Group 1 | 0.05 | −0.04 to 0.14 | 0.06 | −0.03 to 0.14 |
| Group 2 | 0.04 | −0.07 to 0.14 | 0.05 | −0.06 to 0.16 |
| Group 3 | 0.09 | 0.00 to 0.18 | 0.11 | 0.02 to 0.20 |
| Individual congeners | ||||
| PCB-18 | 0.03 | −0.05 to 0.10 | 0.03 | −0.04 to 0.10 |
| PCB-28 | 0.01 | −0.06 to 0.08 | 0.02 | −0.06 to 0.08 |
| PCB-44 | 0.03 | −0.05 to 0.10 | 0.03 | −0.04 to 0.11 |
| PCB-49 | 0.02 | −0.06 to 0.09 | 0.02 | −0.05 to 0.09 |
| PCB-52 | 0.03 | −0.05 to 0.11 | 0.03 | −0.05 to 0.11 |
| PCB-66 | 0.00 | −0.08 to 0.08 | 0.01 | −0.07 to 0.09 |
| PCB-74 | 0.03 | −0.07 to 0.12 | 0.03 | −0.06 to 0.13 |
| PCB-99 | 0.09 | −0.00 to 0.18 | 0.11 | 0.02 to 0.21 |
| PCB-101 | 0.08 | 0.02 to 0.15 | 0.09 | 0.03 to 0.16 |
| PCB-118 | 0.01 | −0.08 to 0.11 | 0.03 | −0.07 to 0.13 |
| PCB-138 | 0.07 | −0.01 to 0.15 | 0.09 | 0.01 to 0.18 |
| PCB-146 | 0.06 | −0.02 to 0.14 | 0.07 | −0.01 to 0.15 |
| PCB-153 | 0.07 | −0.01 to 0.15 | 0.08 | 0.00 to 0.17 |
| PCB-156 | 0.04 | −0.03 to 0.11 | 0.05 | −0.03 to 0.12 |
| PCB-180 | 0.08 | 0.00 to 0.15 | 0.09 | 0.01 to 0.17 |
| PCB-183 | 0.12 | 0.05 to 0.19 | 0.13 | 0.05 to 0.20 |
| PCB-187 | 0.09 | 0.02 to 0.16 | 0.09 | 0.02 to 0.17 |
| PCB-194 | 0.11 | 0.03 to 0.19 | 0.12 | 0.04 to 0.20 |
| PCB-199 | 0.14 | 0.07 to 0.22 | 0.14 | 0.07 to 0.22 |
Models adjusted for neonatal age at time of heel stick for TSH measurement, gestational age at birth, infant birth-weight, sex and mother’s prepregancy BMI.
Sum of all PCBs with a detection frequency ≥ 75%.
Enzyme inducers include PCBs 52, 99, 101, 118, 153, 156, 180, 183, 187, 194, and 199.
Mono-ortho PCBs include PCBs 28, 66, 74, 118, and 156.
Di-ortho PCBs include PCBs 18, 44, 49, 52, 99, 101, 138, 146, 153, 180, and 194.
Group 1 includes PCBs 44, 49, 52, 101, 187, and 199.
Group 2 includes PCBs 66, 74, 118, 138, and 156.
Group 3 includes PCBs 99, 153, 180, and 183.
Figure 1Association between covariate-adjusted TSH levels and the sum of microsomal enzyme-inducing PCB congeners in neonates (n = 285).